CN102970871A - 药物组合物及其制备方法 - Google Patents

药物组合物及其制备方法 Download PDF

Info

Publication number
CN102970871A
CN102970871A CN2011800333447A CN201180033344A CN102970871A CN 102970871 A CN102970871 A CN 102970871A CN 2011800333447 A CN2011800333447 A CN 2011800333447A CN 201180033344 A CN201180033344 A CN 201180033344A CN 102970871 A CN102970871 A CN 102970871A
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition according
cyclodextrin
pazopanib
modified cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800333447A
Other languages
English (en)
Chinese (zh)
Inventor
M.K.古普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Wellcome Manufacturing Pte Ltd
Original Assignee
Glaxo Wellcome Manufacturing Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Manufacturing Pte Ltd filed Critical Glaxo Wellcome Manufacturing Pte Ltd
Publication of CN102970871A publication Critical patent/CN102970871A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2011800333447A 2010-05-05 2011-05-05 药物组合物及其制备方法 Pending CN102970871A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
US61/331,715 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (1)

Publication Number Publication Date
CN102970871A true CN102970871A (zh) 2013-03-13

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800333447A Pending CN102970871A (zh) 2010-05-05 2011-05-05 药物组合物及其制备方法

Country Status (26)

Country Link
US (3) US20120028918A1 (OSRAM)
EP (1) EP2566331B1 (OSRAM)
JP (1) JP5835717B2 (OSRAM)
KR (1) KR20130071434A (OSRAM)
CN (1) CN102970871A (OSRAM)
AR (1) AR081364A1 (OSRAM)
AU (1) AU2011247995B2 (OSRAM)
BR (1) BR112012028291A2 (OSRAM)
CA (1) CA2798386A1 (OSRAM)
CL (1) CL2012003075A1 (OSRAM)
CO (1) CO6640262A2 (OSRAM)
CR (1) CR20120556A (OSRAM)
DO (1) DOP2012000281A (OSRAM)
EA (1) EA201291168A1 (OSRAM)
ES (1) ES2519615T3 (OSRAM)
IL (1) IL222751A0 (OSRAM)
MA (1) MA34286B1 (OSRAM)
MX (1) MX2012012837A (OSRAM)
NZ (1) NZ603411A (OSRAM)
PE (1) PE20130217A1 (OSRAM)
PH (1) PH12012502159A1 (OSRAM)
SG (1) SG185087A1 (OSRAM)
TW (1) TW201206908A (OSRAM)
UY (1) UY33367A (OSRAM)
WO (1) WO2011140343A1 (OSRAM)
ZA (1) ZA201208265B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106551A (zh) * 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
JP2015507020A (ja) * 2012-02-17 2015-03-05 ファーマサイクリックス，インク． ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用
US9629021B2 (en) * 2012-03-08 2017-04-18 Samsung Electronics Co., Ltd Method for controlling service in radio communication system
AU2014236455B2 (en) * 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
WO2016104690A1 (ja) 2014-12-25 2016-06-30 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
US11174253B2 (en) 2017-08-02 2021-11-16 Alphala Co., Ltd. Compound and pharmaceutical composition containing the same
SI3810089T1 (sl) * 2018-06-07 2023-11-30 Pfizer Inc. Vodna formulacija,ki vsebuje 1-(4-((4-(dimetilamino)piperidin-1-il)karbonil)fenil)-3-(4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil)sečnino
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374522A (zh) * 2006-01-27 2009-02-25 安姆根有限公司 Ang2和vegf抑制剂的组合
CN101484006A (zh) * 2006-04-18 2009-07-15 Ekr治疗公司 预混和的、立即可用的ⅳ推注组合物和使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CA2711759A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
CN102573477A (zh) * 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
US20120232102A1 (en) * 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374522A (zh) * 2006-01-27 2009-02-25 安姆根有限公司 Ang2和vegf抑制剂的组合
CN101484006A (zh) * 2006-04-18 2009-07-15 Ekr治疗公司 预混和的、立即可用的ⅳ推注组合物和使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106551A (zh) * 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用

Also Published As

Publication number Publication date
UY33367A (es) 2011-10-31
HK1175947A1 (en) 2013-07-19
DOP2012000281A (es) 2013-05-31
CO6640262A2 (es) 2013-03-22
AU2011247995B2 (en) 2014-07-31
CL2012003075A1 (es) 2013-03-08
BR112012028291A2 (pt) 2015-09-15
IL222751A0 (en) 2012-12-31
AR081364A1 (es) 2012-08-29
US20110281901A1 (en) 2011-11-17
EP2566331B1 (en) 2014-09-03
PH12012502159A1 (en) 2013-02-04
AU2011247995A1 (en) 2012-12-13
PE20130217A1 (es) 2013-03-21
CA2798386A1 (en) 2011-11-10
EA201291168A1 (ru) 2013-06-28
CR20120556A (es) 2013-02-20
TW201206908A (en) 2012-02-16
KR20130071434A (ko) 2013-06-28
JP2013525501A (ja) 2013-06-20
NZ603411A (en) 2014-10-31
EP2566331A4 (en) 2013-09-18
SG185087A1 (en) 2012-12-28
MX2012012837A (es) 2013-01-24
ZA201208265B (en) 2013-07-31
ES2519615T3 (es) 2014-11-07
EP2566331A1 (en) 2013-03-13
US20120028918A1 (en) 2012-02-02
MA34286B1 (fr) 2013-06-01
US20150231265A1 (en) 2015-08-20
WO2011140343A1 (en) 2011-11-10
JP5835717B2 (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
AU2011247995B2 (en) Pharmaceutical compositions and methods of making same
CA2668733C (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
BR112012033077B1 (pt) composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
Alqurshi et al. In-situ freeze-drying-forming amorphous solids directly within capsules: An investigation of dissolution enhancement for a poorly soluble drug
Sugihara et al. Evaluation of pazopanib phase behavior following pH-induced supersaturation
Bahr et al. Understanding the role of sodium lauryl sulfate on the biorelevant solubility of a combination of poorly water-soluble drugs using high throughput experimentation and mechanistic absorption modeling
CN101484136A (zh) 预混合的、立即可用的药物组合物
EP1205181B1 (en) Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt
KR20250024925A (ko) 수성 티카그렐러 용액, 제조 방법 및 용도
US20130023550A1 (en) Pharmaceutical compositions and methods of making same
JPWO2008023807A1 (ja) 安定化された医薬組成物
JP5189980B2 (ja) 可溶化剤として酸を含むアルガトロバン処方物
CN111249229A (zh) 一种稳定的法匹拉韦注射液及其制备方法
Patil et al. Formulation evaluation of extended-release solid dispersion of metformin hydrochloride
Shah et al. Exploring of Taguchi design in the optimization of brinzolamide and timolol maleate ophthalmic in-situ gel used in treatment of glaucoma
WO2008087076A1 (en) Pharmaceutical composition of improved stability containing taxane derivatives
CN106061507A (zh) 包含苯海拉明的稳定的液体药物
CN106551898A (zh) 一种富马酸沃诺拉赞组合物及其制备方法
CN102204882B (zh) 布洛芬的药物组合物
JP5624281B2 (ja) 光安定性に優れたキノロン系抗菌薬含有液体製剤
CN102362855B (zh) 一种伊曲康唑异构体口服溶液
US20230000814A1 (en) Pharmaceutical composition comprising steroid compound and olopatadine
HK1175947B (en) Pharmaceutical compositions and methods of making same
Kulkarni et al. Solubility enhancement of water insoluble drug for ophthalmic formulation
Carpenter et al. Stability of omeprazole sodium and pantoprazole sodium diluted for intravenous infusion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130313